Pimecrolimus Cream 1%: A Potential New Treatment for Chronic Hand Dermatitis

Cutis

Volumn 73, Issue 1, 2004, Pages 31-38

  Belsito, Donald V ^a   Fowler Jr , Joseph F ^b   Marks Jr , James G ^c   Pariser, David M ^d   Hanifin, Jon ^e   Gomes Duarte, Ida Alzira ^f   Pires, Mario C ^g   Cruz Jr , Ponciano D ^h   Langley, Richard G B ⁱ   Patel, Premal ^j   Bush, Christopher ^j   Thurston, Mark ^j   Graeber, Michael ^k   Cherill, Robert ^j  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f S Casa de Misericordia de S Paulo   (Brazil)

^g Hospital do Publico Estadual   (Brazil)

^h Univ of TX Southwestern Med Center   (United States)

ⁱ QE2 Health Science Center   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k Novartis Pharma AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ARTICLE; BURNING SENSATION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HAND DISEASE; HUMAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STRATIFICATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; EMOLLIENTS; FEMALE; FOLLOW-UP STUDIES; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; TACROLIMUS; TREATMENT OUTCOME;

EID: 10744225363     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Smit HA, Burdorf A, Coenraads PJ. Prevalence of hand dermatitis in different occupations. Int J Epidemiol. 1993;22:288-293.
2. Meding B. Epidemiology of hand eczema. In: Menne T, Maibach HI, eds. Hand Eczema. 2nd ed. Boca Raton, Fla: CRC Press; 2000:15-27.
3. Coenraads PJ, Diepgen TL. Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health. 1998;71:7-13.
4. Svensson A. Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol. 1988;68:509-513.
5. Agner T. Guidelines for the management of hand eczema. In: Menne T, Maibach HI, eds. Hand Eczema. 2nd ed. Boca Raton, Fla: CRC Press; 2000:361-367.
6. Woolner D, Soltani K. Management of hand dermatitis. Compr Ther. 1994;20:422-426.
7. Veien NK, Olholm Larsen P, Thestrup-Pedersen K, et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140:882-886.
8. Epstein E. Hand dermatitis: practical management and current concepts. J Am Acad Dermatol. 1984;10:395-424.
9. Sheu HM, Chang CH. Alterations in water content of the stratum corneum following long-term topical corticosteroids. J Formos Med Assoc. 1991;90:664-669.
10. Fowler JF Jr. Efficacy of a skin-protective foam in the treatment of chronic hand dermatitis. Am J Contact Dermat. 2000;11:165-169.
11. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264-273.
12. Cherill R, Tofte S, MacNaul R, et al. 1% SDZ ASM 981 cream effective in the treatment of chronic irritant hand dermatitis: a 6-week, randomized, double-blind, vehicle-controlled, single-center study. J Eur Acad Dermatol Venereol. 2000;14:P128.
13. Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health. 1999;72:496-506.
14. H. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997;137:568-576.
15. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000;42:349-350.
16. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs. 2002;62:817-840.
17. Wahn U, Pariser D, Gottlieb AB, et al. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%. In: Programs and Abstracts of the 59th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001, Washington, DC. P95.
18. Thaci D, Steinmeyer K, Ebelin M-E, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology. 2003;207:37-42.